Dr. Mark S Dacey , MD
Ophthalmology • Denver, CO
425 S Cherry St Ste 907
Denver, CO 802461242
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on June 7, 2007; this date does not establish years in practice.
-
Published CMS data list 3,296 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- 92134 — Imaging of retina: 994 service units.
- 92014 — Established patient complete exam of visual system: 711 service units.
- 99214 — Established patient outpatient office visit: 356 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 15 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 1,929 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Prednisolone Acetate — 260 prescription fills, including refills.
- Methotrexate (Methotrexate Sodium) — 222 prescription fills, including refills.
- Difluprednate — 188 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 28 records in the table · Guide: How to read Medicare Part D prescriber data
-
More Medicare Part B services than 80% of clinicians listed under Ophthalmology in Denver, CO (2024, 38 clinicians with data). Median for this group: 1,558. Middle half: 601 to 2,461.
More Medicare Part B services than 80% of clinicians listed under Ophthalmology in Colorado (2024, 172 clinicians with data). Median for this group: 1,738. Middle half: 809 to 3,050.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 2,713 in 2020 to 3,296 in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020–2024.
Practice Location & Contact Primary Location
425 S Cherry St Ste 907
Denver, CO 802461242
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
NPPES lists 1 additional practice-address record in Colorado Springs, CO. See the list
Source: CMS NPPES NPI Registry, practice location records; release date unavailable.
Listings do not confirm current availability, employment or a shared ownership network.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File
University Of Michigan Medical School
2005
What Public CMS Data Show
Ophthalmology: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
361 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.
Medicare-allowed amount
About $448,136 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
Paid by Medicare
About $343,340 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
30-day fills
2,977 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$1,503,128 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $26,071.32 across 37 records.
By nature of payment (3 largest of 6)
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program: $10,875.00 across 4 records.
- Consulting Fee: $9,100.00 across 3 records.
- Honoraria: $3,425.00 across 2 records.
Reporting-company totals (3 largest of 4)
- ABBVIE INC.: $11,701.98 across 16 records.
- Genentech, Inc.: $7,177.18 across 7 records.
- ANI Pharmaceuticals, Inc.: $3,612.45 across 8 records.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
21 years (graduated 2005)
CMS Doctors and Clinicians data list 2005 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File.
NPI first issued
2007
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Dr. Dacey has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Dacey as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Denver and Colorado
Billing and prescribing volume is not a quality rating.
Medicare Part B services
More Medicare Part B services than 80% of clinicians listed under Ophthalmology in Denver, CO (2024, 38 clinicians with data). Median for this group: 1,558. Middle half: 601 to 2,461.
More Medicare Part B services than 80% of clinicians listed under Ophthalmology in Colorado (2024, 172 clinicians with data). Median for this group: 1,738. Middle half: 809 to 3,050.
Medicare-allowed amount
A higher Medicare-allowed amount than 85% of clinicians listed under Ophthalmology in Denver, CO (2024, 38 clinicians with data). Median for this group: $210,570. Middle half: $62,915 to $319,073.
A higher Medicare-allowed amount than 75% of clinicians listed under Ophthalmology in Colorado (2024, 172 clinicians with data). Median for this group: $235,530. Middle half: $94,144 to $410,263.
Paid by Medicare
A higher Medicare payment amount than 85% of clinicians listed under Ophthalmology in Denver, CO (2024, 38 clinicians with data). Median for this group: $151,727. Middle half: $42,386 to $244,018.
A higher Medicare payment amount than 75% of clinicians listed under Ophthalmology in Colorado (2024, 172 clinicians with data). Median for this group: $168,350. Middle half: $67,511 to $302,828.
Medicare Part D prescriptions
More Part D prescriptions than 85% of clinicians listed under Ophthalmology in Denver, CO (2024, 48 clinicians with data). Median for this group: 676. Middle half: 264 to 1,219.
More Part D prescriptions than 80% of clinicians listed under Ophthalmology in Colorado (2024, 213 clinicians with data). Median for this group: 725. Middle half: 267 to 1,409.
Part D drug cost
A higher Part D drug cost than 95% of clinicians listed under Ophthalmology in Denver, CO (2024, 48 clinicians with data). Median for this group: $40,256. Middle half: $8,398 to $133,488.
A higher Part D drug cost than 95% of clinicians listed under Ophthalmology in Colorado (2024, 213 clinicians with data). Median for this group: $54,562. Middle half: $8,953 to $125,322.
82 active clinicians are listed under Ophthalmology with a practice address in Denver, CO (337 in Colorado).
Addresses are self-reported to NPPES and may be out of date.
Telehealth indicator in Denver
1.2% of these 82 clinicians have the CMS telehealth indicator.
56.1% of these 82 clinicians are listed by CMS as accepting Medicare assignment.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services increased 21% from 2,713 in 2020 to 3,296 in 2024.
- 2020: 2,713
- 2021: 2,968
- 2022: 2,704
- 2023: 2,636
- 2024: 3,296
-
Medicare-allowed amount
Medicare-allowed amount increased 21% from $370,065 in 2020 to $448,136 in 2024.
- 2020: $370,065
- 2021: $421,615
- 2022: $386,912
- 2023: $354,307
- 2024: $448,136
-
Paid by Medicare
Paid by Medicare increased 21% from $282,825 in 2020 to $343,340 in 2024.
- 2020: $282,825
- 2021: $324,519
- 2022: $295,804
- 2023: $268,369
- 2024: $343,340
-
Medicare Part D prescriptions
Medicare Part D prescriptions increased 23% from 1,572 in 2020 to 1,929 in 2024.
- 2020: 1,572
- 2021: 1,698
- 2022: 1,762
- 2023: 1,829
- 2024: 1,929
-
30-day fills
30-day fills increased 29% from 2,309 in 2020 to 2,977 in 2024.
- 2020: 2,309
- 2021: 2,442
- 2022: 2,631
- 2023: 2,731
- 2024: 2,977
-
Part D drug cost
Part D drug cost increased 68% from $893,745 in 2020 to $1,503,128 in 2024.
- 2020: $893,745
- 2021: $1,039,036
- 2022: $1,129,608
- 2023: $1,406,776
- 2024: $1,503,128
-
Industry payments (Open Payments)
Industry payments (Open Payments) increased 64% from $15,884.78 in 2021 to $26,071.32 in 2025.
- 2021: $15,884.78
- 2022: $46,431.86
- 2023: $30,795.97
- 2024: $119,622.79
- 2025: $26,071.32
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 37 records totaling $26,071.32.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Genentech, Inc. |
Consulting Fee
Cash or cash equivalent
|
— | General | $6,100.00 |
| ABBVIE INC. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
OZURDEX | General | $5,250.00 |
| ABBVIE INC. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
OZURDEX | General | $2,250.00 |
| ABBVIE INC. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
OZURDEX | General | $2,250.00 |
| Bausch & Lomb Americas Inc. |
Consulting Fee
Cash or cash equivalent
|
XIPERE | General | $2,000.00 |
| ANI Pharmaceuticals, Inc. |
Honoraria
Cash or cash equivalent
|
PURIFIED CORTROPHIN GEL | General | $1,850.00 |
| ANI Pharmaceuticals, Inc. |
Honoraria
Cash or cash equivalent
|
YUTIQ | General | $1,575.00 |
| ABBVIE INC. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
OZURDEX | General | $1,125.00 |
| Bausch & Lomb Americas Inc. |
Consulting Fee
Cash or cash equivalent
|
XIPERE | General | $1,000.00 |
| Bausch & Lomb Americas Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
XIPERE | General | $500.00 |
| ABBVIE INC. |
Travel and Lodging
In-kind items and services
|
OZURDEX | General | $386.96 |
| Genentech, Inc. |
Travel and Lodging
In-kind items and services
|
— | General | $366.18 |
| Genentech, Inc. |
Travel and Lodging
Cash or cash equivalent
|
— | General | $240.08 |
| Genentech, Inc. |
Travel and Lodging
In-kind items and services
|
— | General | $231.30 |
| ABBVIE INC. |
Travel and Lodging
In-kind items and services
|
OZURDEX | General | $129.67 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
OZURDEX | General | $124.99 |
| ANI Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
PURIFIED CORTROPHIN GEL | General | $124.22 |
| Genentech, Inc. |
Food and Beverage
In-kind items and services
|
— | General | $83.33 |
| Genentech, Inc. |
Food and Beverage
In-kind items and services
|
— | General | $83.33 |
| Genentech, Inc. |
Food and Beverage
In-kind items and services
|
— | General | $72.96 |
| ABBVIE INC. |
Travel and Lodging
In-kind items and services
|
OZURDEX | General | $45.00 |
| ABBVIE INC. |
Travel and Lodging
In-kind items and services
|
OZURDEX | General | $33.98 |
| Bausch & Lomb Americas Inc. |
Food and Beverage
In-kind items and services
|
XIPERE | General | $31.35 |
| ABBVIE INC. |
Travel and Lodging
In-kind items and services
|
OZURDEX | General | $26.60 |
| Bausch & Lomb Americas Inc. |
Food and Beverage
In-kind items and services
|
XIPERE | General | $24.33 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
92134
Imaging of retina
|
994 | 265 | $105.66 | $42.77 |
|
92014
Established patient complete exam of visual system
|
711 | 249 | $331.00 | $133.76 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
356 | 186 | $330.71 | $135.83 |
|
99426
Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month
|
253 | 47 | $125.00 | $66.06 |
|
J0178
Injection, aflibercept, 1 mg
|
204 | 20 | $1965.00 | $824.89 |
|
67028
Injection of drug into eye
|
132 | 36 | $500.00 | $132.67 |
|
92250
Photography of the retina
|
120 | 54 | $112.43 | $38.22 |
|
92235
Exam of retinal blood vessels using a special camera after injection of a dye
|
116 | 66 | $338.14 | $176.84 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
104 | 71 | $233.00 | $96.74 |
|
92012
Established patient problem focused exam of visual system
|
98 | 69 | $235.79 | $95.58 |
|
99427
Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month
|
75 | 34 | $97.00 | $50.53 |
|
G2211
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
|
65 | 47 | $40.54 | $17.08 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
40 | 40 | $440.60 | $176.14 |
|
92004
New patient complete exam of visual system
|
14 | 14 | $389.00 | $160.33 |
|
92083
Exam of visual field with extended testing
|
14 | 13 | $162.00 | $67.32 |
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 260 | 13,323 | $13,481.84 | 104 |
| Methotrexate | Methotrexate Sodium | 222 | 9,802 | $4,360.19 | 41 |
| Difluprednate | Difluprednate | 188 | 5,190 | $18,411.87 | 55 |
| Timolol Maleate | Timolol Maleate | 129 | 6,472 | $1,354.24 | 43 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 113 | 4,830 | $15,944.93 | 23 |
| Humira(Cf) Pen | Adalimumab | 110 | 3,304 | $1,054,645.69 | 12 |
| Latanoprost | Latanoprost | 104 | 4,767 | $837.03 | 25 |
| Valacyclovir | Valacyclovir Hcl | 90 | 4,352 | $6,891.25 | 27 |
| Brimonidine Tartrate | Brimonidine Tartrate | 90 | 5,162 | $993.34 | 36 |
| Prednisone | Prednisone | 81 | 2,581 | $646.07 | 20 |
| Dorzolamide Hcl | Dorzolamide Hcl | 78 | 5,237 | $947.31 | 24 |
| Loteprednol Etabonate | Loteprednol Etabonate | 62 | 2,095 | $9,900.38 | 26 |
| Simbrinza | Brinzolamide/Brimonidine Tart | 48 | 2,176 | $11,217.48 | — |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 44 | 2,288 | $5,266.83 | 22 |
| Humira(Cf) | Adalimumab | 39 | 1,092 | $320,840.36 | — |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | 2,645 | $805.82 | 13 |
| Mycophenolic Acid | Mycophenolate Sodium | 32 | 1,680 | $6,524.92 | — |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 31 | 1,312 | $574.62 | — |
| Folic Acid | Folic Acid | 25 | 1,770 | $211.84 | — |
| Erythromycin | Erythromycin Base | 22 | 384 | $231.12 | 21 |
| Zirgan | Ganciclovir | 21 | 592 | $10,897.41 | — |
| Valganciclovir Hcl | Valganciclovir Hcl | 21 | 630 | $2,140.50 | — |
| Acyclovir | Acyclovir | 18 | 720 | $305.51 | — |
| Combigan | Brimonidine Tartrate/Timolol | 17 | 820 | $4,853.17 | — |
| Restasis | Cyclosporine | 14 | 480 | $9,355.11 | — |
(top 25 shown)
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
Self-certified to NPPES: 2025-03-18NUCC Taxonomy Code: 207W00000X
An ophthalmologist has the knowledge and professional skills needed to provide comprehensive eye and vision care. Ophthalmologists are medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, an ophthalmologist prescribes vision services, including glasses and contact lenses.
NUCC Taxonomy Code: 207WX0108X
An ophthalmologist who specializes in the treatment of intraocular inflammation, scleritis, keratitis and infectious disorders affecting the eye and inflammatory disorders of the adnexa and/or orbit.
Additional State Medicaid & Healthcare Payer Identifiers
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - OPHTHALMOLOGY
I20110607000375
CO
9436204344
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Secondary Practice Locations
10035 Pearl Pass Vw Ste 110
Colorado Springs, CO 809248223
Phone: 7208266422
Career & Practice History Timeline
Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status
Registered at 425 S CHERRY ST STE 907, DENVER, CO 802461242 (Tel: 2082664227)
Registered at 425 S CHERRY ST STE 907, DENVER, CO 802461242 (Tel: 2082664227)
Additional practice office at 10035 Pearl Pass Vw Ste 110, Colorado Springs, CO 809248223
Ophthalmology (license number reported to NPPES: CO 49002)
Registered at 11960 LIONESS WAY STE 290, PARKER, CO 801345640 (Tel: 3032611600)
NPI status registered as active in NPPES database
Registered at 8101 E LOWRY BLVD, STE 210, DENVER, CO 802307195 (Tel: 3032611600)
Registered at 8101 E LOWRY BLVD, SUITE 210, DENVER, CO 802307196 (Tel: 3032611600)
Recorded as MARK DACEY, MD
Ophthalmology (license number reported to NPPES: CO 49002)
NPI status registered as active in NPPES database
Registered at 8101 E LOWRY BLVD, SUITE 210, DENVER, CO 802307196 (Tel: 3032611600)
Registered at 850 E HARVARD AVE, SUITE 155, DENVER, CO 802105073 (Tel: 3037781910)
Recorded as MARK DACEY, MD
Ophthalmology (license number reported to NPPES: CO 49002)
First registered as active Individual Practitioner in NPPES Database.
NPI Administrative Meta
Other Ophthalmology Specialists in Denver
- Dr. Yash Vaishnav, MD
- Dr. Howard Amiel, MD, MS
- Dr. Joel Goldstein, MD
- Dr. Carl Hanson, MD
- Dr. Stuart Lewis, MD
- Dr. Sumit Sitole, MD
Mailing Address
425 S Cherry St Ste 907
Denver, CO 802461242
Phone: 2082664227